Evaluation of Lineage/Site-specific Nuclear Immunohistochemical Markers SATB2, Cyclin D1, SALL4, and BCOR in High-grade Endometrial Carcinomas
- 11 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 42 (5) , 443-450
Abstract
Poorly differentiated malignant neoplasms involving the gynecologic tract routinely include a poorly differentiated endometrial carcinoma (EC) in the differential diagnosis. Some nuclear lineage/site-specific immunohistochemical markers are utilized in this diagnostic setting including SATB2, cyclin D1, SALL4, and BCOR, but their specificity and use in small samples are not clear across the spectrum of ECs. Cases of undifferentiated/dedifferentiated endometrial carcinomas (UEC/DDEC), clear cell carcinoma (CCC), uterine serous carcinoma (USC), FIGO grade 3 endometrial endometrioid carcinoma (EEC), and uterine carcinosarcoma (UCS) were identified and diagnoses confirmed. Whole-section immunohistochemical stains for SATB2, cyclin D1, SALL4, BCOR, and PAX8 were performed. A total of 113 cases were utilized: 15 CCC, 26 EEC, 19 UCS, 22 USC, and 31 UEC/DDEC. Cases were distributed across both low (49%) and high (51%) FIGO clinical stages. SATB2 was expressed by UCS (8/19, 42%), EEC (10/26, 38%), UEC/DDEC (11/30, 37%), and USC (6/22, 27%). Cyclin D1 was expressed by EEC (24/26, 92%), USC (17/22, 77%), UEC/DDEC (15/20 EEC component, 75%; 22/30 UEC, 73%), UCS (10/16 carcinoma, 63%; 11/19 sarcoma, 58%), and CCC (8/15, 53%). SALL4 was expressed most frequently by UEC/DDEC (12/30, 40%), but also USC (7/22, 32%), EEC (5/26, 19%), and UCS (4/16 carcinoma, 25%; 3/19 sarcoma, 16%). BCOR was expressed at low levels in 2 USC, 2 UEC/DDEC, and 2 UCS. PAX8 was generally positive but showed lower expression in UEC/DDEC (17/30, 57%) and in the sarcomatous portions of UCS (6/19, 32%). SATB2, cyclin D1, SALL4, and BCOR stain variable numbers of poorly-differentiated EC and must be carefully interpreted within morphologic and clinical context.Keywords
This publication has 43 references indexed in Scilit:
- CyclinD1, a prominent prognostic marker for endometrial diseasesDiagnostic Pathology, 2013
- Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 RearrangementAmerican Journal of Surgical Pathology, 2012
- Immunoexpression of PAX 8 in Endometrial CancerInternational Journal of Gynecological Pathology, 2011
- SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal CarcinomasAmerican Journal of Surgical Pathology, 2011
- A Comprehensive Analysis of PAX8 Expression in Human Epithelial TumorsAmerican Journal of Surgical Pathology, 2011
- PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical studyLaboratory Investigation, 2011
- SALL4 Is a Novel Diagnostic Marker for Testicular Germ Cell TumorsAmerican Journal of Surgical Pathology, 2009
- SALL4 Is a Novel Sensitive and Specific Marker of Ovarian Primitive Germ Cell Tumors and Is Particularly Useful in Distinguishing Yolk Sac Tumor From Clear Cell CarcinomaAmerican Journal of Surgical Pathology, 2009
- Molecular alterations associated with cyclin d1 overexpression in endometrial cancerInternational Journal of Cancer, 2004
- Cyclin D1 gene (CCND1) mutations in endometrial cancerOncogene, 2003